Modus Therapeutics Holding Valuation

Is MODTX undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Below Fair Value
Significantly Below Fair Value
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of MODTX when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate MODTX's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate MODTX's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for MODTX?

Key metric: As MODTX is unprofitable and pre-revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for MODTX. This is calculated by dividing MODTX's market cap by their current book value.
What is MODTX's PB Ratio?
PB Ratio	6.7x
Book	SEK 6.85m
Market Cap	SEK 46.00m

MODTX key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	n/a
Enterprise Value/EBITDA	n/a
PEG Ratio	n/a

Price to Book Ratio vs Peers

How does MODTX's PB Ratio compare to its peers?

The above table shows the PB ratio for MODTX vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PB	Estimated Growth	Market Cap
Peer Average	1.2x
QUIA Quia Pharma	0.9x	n/a	SEK 31.0m
COMBI CombiGene	0.6x	n/a	SEK 52.3m
EXPRS2 ExpreS2ion Biotech Holding	0.6x	-11.9%	SEK 43.8m
ELIC Elicera Therapeutics	2.8x	-18.5%	SEK 64.4m
MODTX Modus Therapeutics Holding	6.7x	-44.9%	SEK 46.0m

Price-To-Book vs Peers: MODTX is expensive based on its Price-To-Book Ratio (6.7x) compared to the peer average (1.2x).

Price to Book Ratio vs Industry

How does MODTX's PB Ratio compare vs other companies in the SE Biotechs Industry?

7 Companies	Price / Book	Estimated Growth	Market Cap
SCOL Scandion Oncology	0.5x	69.7%	US$1.59m
DIABIO Diagonal Bio	0.5x	n/a	US$1.17m
CYXO Cyxone	0.4x	n/a	US$961.22k
PROGEN Prostatype Genomics	0.6x	n/a	US$680.17k

7 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Book vs Industry: MODTX is expensive based on its Price-To-Book Ratio (6.7x) compared to the Swedish Biotechs industry average (2.6x).

Price to Book Ratio vs Fair Ratio

What is MODTX's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

MODTX PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio	6.7x
Fair PB Ratio	n/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate MODTX's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

PMD Device Solutions

SEK 19.5m

A digital medical device company, develops and sells respiratory monitoring solutions in Ireland.

PMDS

SEK 0.75

-44.9%

n/a

AstraZeneca

UK£164.5b

A biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines.

AZN

UK£1,471.00

0.6%

9.1%

Ascelia Pharma

SEK 278.6m

A biotech company, focuses on orphan oncology treatments in Sweden.

ACE

SEK 2.90

7.0%

5.5%